2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Duration of response is good too. Talquetamab (JNJ-64407564) is a bispecific IgG4 antibody that redirects T-cell killing to multiple myeloma cells by binding to the novel target, GPRC5D, and CD3. Rich completed his Masters degree in the Arts back in 2013 before joining New Atlas in 2016. Dermatologic TEAEs were reported by 48.7% (n = 37) of patients in this trial. Thanks for the information in this one in particular. New blood cancer therapy successful in three-quarters of trial patients Aronson E. Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myeloma. MNT is the registered trade mark of Healthline Media. By The ASCO Post Staff Back pain can be a symptom of cancer or a side effect of cancer treatment. Myeloma Bispecific Antibody Talquetamab Update - HealthTree for Myeloma Taltz is a medicine used for treating moderate to severe plaque psoriasis, a disease causing red, scaly patches on the skin. The range for dosing was biweekly or weekly treatment at a dosage of 1.5 to 180 g/kg with IV administration and 5 to 800 g/kg with subcutaneous treatment. Kikuchi T, Tsukada N, Nomura M, Kasuya Y, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Ishida T. Ann Hematol. Oral TEAEs were common in the trial with 57.9% of patients (n = 44) experiencing a grade 1 or 2 oral AE. Talquetamab binds to both T cells and multiple myeloma cells. Careers. In June 2022, the FDA granted talquetamab a breakthrough therapy designation.3. Talquetamab is a bispecific antibody, a type of monoclonal antibody that redirects T cells to act against myeloma cells. For nail changes, Aronson recommends nail hardeners, Vitamin E lotion, and cuticle care products. Disclosure: This study was funded by Janssen Research & Development LLC. And a new kind of drug from Argenx was included in the meetings highlights, with updated results detailing another potential use of the biotechnology companys medicine. Just under three-quarters of participants given a lower or higher dose of talquetamab in the Phase 2 portion of J&Js study responded to treatment, with around a third of each group achieving remission of their cancer. I tell patients to take a lukewarm or cool shower, [to use] heavy lubricants, body oil, those kinds of thingsbecause the dryness is really severe. Potentially Serious Side Effect Seen in Patient after Immunotherapy New blood cancer therapy successful in three-quarters of trial patients, The new treatment is currently under application for review by the FDA. We've been so busy adding drugs to the arsenal that [were] catching up to figure out the right sequences and unanswered questions..
talquetamab side effects